<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154670</url>
  </required_header>
  <id_info>
    <org_study_id>145-RI-102</org_study_id>
    <nct_id>NCT04154670</nct_id>
  </id_info>
  <brief_title>Study Assessing PK and Safety of MGTA-145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment</brief_title>
  <official_title>An Open Label, Single Arm, Single Dose Study to Evaluate the Pharmacokinetics and Safety and Tolerability of MGTA 145 in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Magenta Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Magenta Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted in healthy subjects and in subjects with a mild or moderate
      decrease in GFR (subjects with renal impairment).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MGTA-145
      in Subjects With Normal Estimated GFR and Varying Degrees of Renal Impairment
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 7, 2019</start_date>
  <completion_date type="Actual">March 24, 2020</completion_date>
  <primary_completion_date type="Actual">March 24, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics Biomarkers</measure>
    <time_frame>2 days</time_frame>
    <description>Investigate area under the curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Biomarkers</measure>
    <time_frame>2 days</time_frame>
    <description>Investigate maximum plasma concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Biomarkers</measure>
    <time_frame>2 days</time_frame>
    <description>Investigate clearance (CL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Biomarkers</measure>
    <time_frame>2 days</time_frame>
    <description>volume of distribution at steady state (Vdss)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Biomarkers</measure>
    <time_frame>2 days</time_frame>
    <description>Investigate half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics Biomarkers</measure>
    <time_frame>2 days</time_frame>
    <description>Investigate renal clearance of MGTA-145</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>15 days</time_frame>
    <description>Investigate the safety and tolerability of MGTA-145 following intravenous (IV) administration as monotherapy in subjects with varying degrees of renal impairment (e.g. adverse events, clinical laboratory tests, vital signs, ECGs)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Healthy</condition>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Normal kidney function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGTA-145 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild decrease in GFR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGTA-145 single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate decrease in GFR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MGTA-145 single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MGTA-145</intervention_name>
    <description>MGTA-145 will be given intravenously</description>
    <arm_group_label>Mild decrease in GFR</arm_group_label>
    <arm_group_label>Moderate decrease in GFR</arm_group_label>
    <arm_group_label>Normal kidney function</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for all subjects:

          1. Age from 18 to 79 years, inclusive, at the time of signing of the ICF.

          2. Body weight ≥50 kg and BMI 19 to 40 kg/m2, inclusive.

          3. Systolic blood pressure ≤170 mmHg and diastolic blood pressure ≤100 mmHg at Screening
             and Day 1.

          4. No clinically significant abnormalities on physical examination at Screening.

          5. Alanine aminotransferase and aspartate aminotransferase up to 1.5 x the upper limit of
             normal (ULN) as long as total bilirubin and alkaline phosphatase are ≤ ULN.

          6. No clinically significant abnormalities on ECG and QTcF &lt;480 msec at Screening.

          7. Female subjects are not pregnant, non-lactating, and must be of non-childbearing
             potential being either surgically sterile (eg, documented hysterectomy, bilateral
             oophorectomy, bilateral salpingo oopherectomy, tubal ligation) or post-menopausal
             women (over 45 years of age with 12 months or more amenorrhea verified by follicle
             stimulating hormone assessment and the absence of other biological or physiological
             causes).

          8. Male subjects who are sexually abstinent or surgically sterilized (vasectomy), or
             those who are sexually active with a female partner(s) and agree to use an acceptable
             method of contraception (such as condom with spermicide) combined with an acceptable
             method of contraception for their non-pregnant female partner(s) after informed
             consent, throughout the study, and for a minimum of 90 days after the last dose, and
             who do not intend to donate sperm in the period from Screening until 3 months
             following administration of the study drug.

          9. Subject using medications known to affect the elimination of serum creatinine (eg,
             cimetidine, trimethoprim) within the past 30 days.

         10. Capable of providing informed consent and willing to comply with the requirements of
             the protocol.

             Specific inclusion criteria for subjects with NORMAL renal function:

         11. Estimated GFR (based on MDRD equation) ≥90 mL/min/1.73 m2 (normal) as determined by an
             average of 2 values obtained at least 48 hours apart within the previous 3 months.

         12. White blood cell (WBC) count, hemoglobin and platelet count within normal limits.
             Absolute neutrophil count of &gt;1500/µL for African Americans and &gt;2000/µL for other
             races.

             Specific inclusion criteria for subjects with RENAL IMPAIRMENT:

         13. Estimated GFR &lt;90 mL/min/1.73 m2 (based on MDRD equation) as determined by an average
             of 2 values obtained at least 48 hours apart and within the previous 3 months.

         14. Stable renal function as determined by &lt;20% difference in serum creatinine obtained on
             2 occasions at least 48 hours apart and within the previous 3 months.

         15. Platelet count ≥100,000/mm3, hemoglobin count ≥10g/dL, WBC count within normal limits.
             Absolute neutrophil count of &gt;1500/µL for African Americans and &gt;2000/µL for other
             races.

        Exclusion criteria for all subjects:

          1. Clinically significant abnormal finding on physical examination conducted at
             Screening. The assessment may be repeated once prior to treatment number assignment.
             If the repeat value(s) remains outside of protocol-specified ranges, the subject will
             be excluded from the study. Note: Re assessment is not allowed for subjects who have a
             positive urine drug screen test at Screening.

          2. History of chronic alcohol or drug abuse within the previous 12 months. Subject has a
             positive pre-study drug/alcohol screen (to include at minimum: amphetamines,
             barbiturates, cocaine, opiates, cannabinoids, benzodiazepines, and myelosuppressive
             drugs). A subject with a positive finding on the drug screen may still be enrolled at
             the discretion of the Investigator if a plausible clinical explanation exists (eg,
             prior or concomitant medication use).

          3. History of kidney transplantation or requiring dialysis or anticipated to initiate
             dialysis during the study period.

          4. Donation of more than 500 mL of blood or plasma within 12 weeks prior to dosing.

          5. Subject smokes more than 10 cigarettes per day (or equivalent) or has done so within 6
             months prior to the Screening Visit.

          6. Acute illness, infection (requiring medical treatment [eg, antibiotics]), or surgery
             within 30 days of dosing.

          7. Seropositive for hepatitis B surface antigen, hepatitis C virus antibody, or human
             immunodeficiency virus.

          8. Subject has received another investigational drug or participated in an
             investigational device study within 30 days prior to dosing.

          9. History of anaphylaxis or clinically important reaction to any drug including
             plerixafor.

             Specific exclusion criteria for subjects with NORMAL renal function:

         10. Any clinically significant laboratory value outside the normal range at Screening. The
             assessment may be repeated once prior to treatment number assignment. If the repeat
             value(s) remains outside of protocol-specified ranges, the subject will be excluded
             from the study. Note: Re assessment is not allowed for subjects who have a positive
             urine drug screen test at Screening.

         11. Any clinically significant hematologic, cardiovascular, pulmonary, central nervous
             system, metabolic, hepatic, or gastrointestinal conditions or history of conditions
             that, in the opinion of the Investigator may place the subject at an unacceptable risk
             as a participant in this study or may interfere with the interpretation of the study
             results.

         12. Subject has used any prescription drugs within 14 days prior to dosing or any dietary
             supplements or non prescription drugs within 7 days prior to dosing unless deemed
             acceptable by the Investigator and Sponsor (Magenta Medical Monitor).

             Specific exclusion criteria for subjects with RENAL IMPAIRMENT:

         13. Presence of acute kidney injury.

         14. Clinically significant laboratory abnormalities excluding those associated with renal
             impairment or the underlying cause of renal disease.

         15. Unstable medical condition or underlying medical condition that has changed within the
             past 90 days.

         16. Presence of laboratory abnormalities or clinically significant medical condition that
             in the opinion of the Investigator may place the subject at an unacceptable risk as a
             participant in this study or may interfere with the interpretation of the study
             results.

         17. Changes in prescription medications within 14 days prior to dosing or anticipated
             changes during the study period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Will Savage, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Magenta Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Orlando Clinical Research Center (OCRC)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance for Multispeciality Research (AMR) Formerly New Orleans Center for Clinical Research (NOCCR)</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 4, 2019</study_first_submitted>
  <study_first_submitted_qc>November 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2019</study_first_posted>
  <last_update_submitted>June 22, 2020</last_update_submitted>
  <last_update_submitted_qc>June 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

